STOCKHOLM, Sweden, May 27, 2003 (PRIMEZONE) -- Diamyd Medical (O-list) (Stockholm:DIAMb) is planning to present its phase II study with the diabetes vaccine Diamyd in a press release on Monday June 16, 2003. The first application of the vaccine is seen to be preventing diabetes patients being treated with tablets from becoming dependent on insulin injections. Further applications are expected to be the prevention of insulin dependency in children and young people who run the risk of developing the illness and increasing the survival capability of insulin producing cells after transplantation.
The first category for the vaccine is seen to be those diabetes patients with antibodies against GAD who are being treated with tablets. The annual market for this patient category is estimated to be SEK 5-10 billion. There are similar markets if the vaccine can be developed to prevent insulin-dependent diabetes in children and young people.
About Diamyd Medical:
Diamyd Medical's business idea is to identify and develop pharmaceutical projects up to and including Phase II. At present Diamyd Medical is running a number of GAD-based development projects and has the licensed rights for this from universities in the US.
For further information, contact Johannes Falk, Diamyd Medical AB (publ), Tel: +46 8-661 00 26, 661 12 25, fax: +46 8-661 63 68 or email: info@diamyd.com, web site: www.diamyd.com
No guarantee is given or implied for the accuracy of any statements on present, historical or future results.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2003/05/27/20030527BIT00650/wkr0001.doc
http://www.waymaker.net/bitonline/2003/05/27/20030527BIT00650/wkr0002.pdf